News & Events
Killing Cancer by Protecting Normal Cells
Although radiation treatments have become much more refined in recent years, it remains a challenge to both sufficiently dose the tumor while sparing the surrounding tissue.
Novel Cancer Vaccine Approach for Brain Tumors
Glioblastoma is the most common aggressive primary brain tumor, and despite advances in standard treatment, the median survival is about 15 months (compared to 4 months without treatment). Researchers at Thomas Jefferson University have been working on a cancer vaccine that would extend that survival by activating the patient’s immune system to fight the brain tumor.
Fighting for Cancer Patients
Abington Health & Jefferson: Reimagining Region’s Health Care
The chief executives of Abington Health and Jefferson announced today that their respective Boards of Trustees have voted to enter into a Letter of Intent and to move forward with a framework for merging the two organizations.
Hormone Loss Could be Involved in Colon Cancer
Some cancers, like breast and prostate cancer, are driven by hormones such as estrogen and testosterone, but to date, there are none that are driven by the lack of a hormone.
Ideas for Innovating Health Care:
Society of Physician Entrepreneurs Event October 25th
All physicians and healthcare providers are welcome to attend the meeting, which features Jeff Joseph, DO, Professor of Anesthesiology at the Sidney Kimmel Medical College at Thomas Jefferson University as one of the speakers. Take part in networking and the Q&A session. The free event is 9 a.m. to 10:30 a.m. in 207 Jefferson Alumni Hall.
New Target for Treatment of Multiple Sclerosis?
A study published in the October, 2014 issue of Nature Medicine points to a new target for the treatment of multiple sclerosis (M.S.).
Circulating Tumor Cells Provide Genomic Snapshot of Breast Cancer
The genetic fingerprint of a metastatic cancer is constantly changing, which means that the therapy that may have stopped a patient’s cancer growth today, won’t necessarily work tomorrow.
MRSA Biofilms in Joint Fluid Make Infections Tough to Tackle; Pre-Treatment with Enzyme Prevents Formation
Thomas Jefferson University scientists, in collaboration with scientists at the National Institutes of Health, come one step closer to understanding why these infections are so tough to tackle. The results could help explain the joint pain caused by different infections, including Lyme disease and why they’re so resistant to antibiotic treatment.
Philadelphia College of Osteopathic Medicine Signs Affiliation Agreement with Jefferson
Members of Philadelphia College of Medicine (PCOM) faculty and staff recently met with representatives from Thomas Jefferson University’s School of Population Health to sign an affiliation agreement.